CytomX Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $68.4M | $26.9M | $59.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $68.7M | $83.4M | $77.7M | $111.6M | $114.2M | $112.9M | $131.6M | $103.9M |
| SG&A Expense | $29.8M | $29.7M | $30.0M | $42.8M | $39.2M | $36.0M | $36.8M | $33.5M |
| Operating Income | $-22.4M | $25.0M | $-6.5M | $-101.3M | $-116.0M | $-80.5M | $-141.5M | $-77.9M |
| Operating Margin | -29.3% | 18.1% | -6.4% | -190.6% | -311.0% | -117.7% | -525.9% | -130.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-17.1M | $32.1M | $3.3M | $-99.3M | $-115.9M | $-78.7M | $-133.3M | $-70.3M |
| Income Tax Expense | $238.0K | $224.0K | $3.9M | $0 | $0 | $-13.9M | $-427.0K | $14.3M |
| Net Income | $-17.4M | $31.9M | $-569.0K | $-99.3M | $-115.9M | $-64.8M | $-132.8M | $-84.6M |
| Net Margin | -22.8% | 23.1% | -0.6% | -186.8% | -310.5% | -94.7% | -493.7% | -142.2% |
| EPS (Basic) | $-0.15 | $0.38 | $-0.01 | $-1.51 | $-1.81 | $-1.40 | $-2.93 | — |
| EPS (Diluted) | $-0.15 | $0.38 | $-0.01 | $-1.51 | $-1.81 | $-1.40 | $-2.93 | — |
| Shares Outstanding (Basic) | 137.9M | 84.4M | 73.8M | 65.7M | 64.1M | 46.1M | 45.3M | 45.1M |
| Shares Outstanding (Diluted) | 137.9M | 84.7M | 73.8M | 65.7M | 64.1M | 46.1M | 45.3M | 45.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |